US Patent

US9962336 — Extended release suspension compositions

Formulation · Assigned to Sun Pharmaceutical Industries Ltd · Expires 2035-05-01 · 9y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method for making a stable extended release suspension composition of an active ingredient.

USPTO Abstract

The present invention relates to a method for preparing a stable extended release suspension composition comprising multiple coated cores of an active ingredient by using a suspension base, wherein the suspension base ensures substantially similar in-vitro dissolution release profile of the active ingredient upon storage of the suspension compositions for at least seven days.

Drugs covered by this patent

Patent Metadata

Patent number
US9962336
Jurisdiction
US
Classification
Formulation
Expires
2035-05-01
Drug substance claim
No
Drug product claim
Yes
Assignee
Sun Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.